Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India
Rhea-AI Summary
Windtree Therapeutics (NASDAQ: WINT) has filed a national phase patent application in India for istaroxime, targeting the prevention and reduction of acute myocardial arrhythmia risks. The patent application, claiming priority to PCT/US2024/058923, focuses on treating irregular heartbeats that can affect heart pumping function.
The filing is particularly significant as it covers India's population of over 1.4 billion people. The patent application is part of Windtree's strategic intellectual property plan as the company prepares for Phase 3 readiness in cardiogenic shock. The technology addresses arrhythmias in patients with heart failure and cardiomyopathy, which can be caused by underlying cardiac disease or heart failure treatments like catecholamines.
Positive
- Strategic IP expansion into India's massive 1.4B population market
- Advancing towards Phase 3 trials in cardiogenic shock
Negative
- None.
Insights
Windtree's Indian patent application for istaroxime represents a significant strategic move for this micro-cap biotech ($2.76M market cap) as it builds its global intellectual property portfolio ahead of Phase 3 trials for cardiogenic shock. This particular patent focuses on arrhythmia prevention - a critical differentiating mechanism that could expand istaroxime's clinical utility beyond the primary cardiogenic shock indication.
The India filing is particularly notable for three reasons:
- It targets the world's most populous country with a growing cardiovascular disease burden - India has approximately 4.5 million patients with heart failure, creating substantial market potential
- It strengthens Windtree's global IP position, potentially making the company more attractive for partnerships or acquisition
- It signals progression toward Phase 3 readiness, a important inflection point for valuation
For investors, this patent application provides tangible evidence that Windtree is executing on its development strategy despite financial resources. The company's focus on securing broad geographic IP protection suggests management anticipates istaroxime could become a commercially viable asset.
However, significant challenges remain. Windtree will need substantial capital to fund Phase 3 trials, and the path from patent filing to Phase 3 completion involves numerous regulatory and clinical hurdles. The company's small market cap indicates investors remain cautious about its ability to successfully commercialize istaroxime without a strategic partner.
WARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announced today that the Company has filed a national phase patent application with the Indian patent office claiming priority to PCT/US2024/058923 entitled, “ISTAROXIME AND DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.”
Arrythmias are irregular heartbeats that can impact the pumping function of the heart. Patients with heart failure and cardiomyopathy are at risk for arrythmias. Arrythmias in these patients can be caused by their underlying cardiac disease or by drugs used to treat the heart failure such as catecholamines. Arrythmias can impair proper filling of the heart with blood and, importantly, cardiac output to the body. Ventricular arrythmias are particularly dangerous and can be fatal.
“India’s population is greater than 1.4 billion people making it a part of our istaroxime strategic intellectual property plan,” said Jed Latkin, CEO of Windtree. “As we prepare for Phase 3 readiness in cardiogenic shock, we plan to obtain intellectual property protection in key markets such as India.”
About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is designed as a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure have demonstrated that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.
Forward Looking Statements
This press release contains statements related to the potential clinical effects of istaroxime; the potential benefits and safety of istaroxime; the clinical development of istaroxime; and our research and development program for treating patients in early cardiogenic shock due to heart failure. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Examples of such risks and uncertainties include, among other things: the Company’s ability to acquire revenue generating subsidiaries; the market’s reaction to potential acquisitions by the Company; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ
What is the purpose of Windtree's (WINT) new patent application in India?
What stage is WINT's istaroxime development for cardiogenic shock?
What medical conditions does WINT's istaroxime patent application target?
What is the patent application number for WINT's istaroxime in India?
